Dr. Randa Loutfi, MD

Dr. Loutfi practices at Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Loutfi's NPI, 1710055264, was assigned on December 1, 2006. Dr. Loutfi graduated from Damascus University Faculty of Medicine in 1986. Dr. Loutfi holds Michigan license 067555.

Dr. Loutfi's primary practice is Henry Ford Hospital, at 2799 W Grand Blvd, Detroit, MI 48202 in Wayne County. The practice phone is (313) 916-2600.

Dr. Loutfi's primary practice is Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Loutfi is also affiliated with Henry Ford West Bloomfield Hospital. The medical group on file is Henry Ford Health. Dmand AI also links Dr. Loutfi to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Loutfi practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Loutfi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Loutfi is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Loutfi's licenses on file in 3 states: Michigan, Illinois and Indiana.

Dmand AI lists breast cancer, chronic anemia, fluid and electrolyte imbalances, lung cancer and prostate cancer among the conditions Dr. Loutfi treats.

CMS data shows 110 Medicare services from Dr. Loutfi across 3 procedure codes in 2024, for 58 Medicare patients. Medicare paid $7,148 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 58 Medicare patients who saw Dr. Loutfi in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have cancer, and 64% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Loutfi's median patient age at 69, with 91% women.

In 2024, Dr. Loutfi wrote 884 Medicare Part D claims for 199 patients. 85% of them were for generic drugs. CMS names the drug for 667 of them, across 21 drugs with 11 or more claims each, at $913,758 in total drug cost. In 2023, CMS named 1,209 claims across 31 drugs.

Dr. Loutfi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Loutfi as offering telehealth.

Dmand AI links 14 papers to Dr. Loutfi, published from 2009 to 2024. 2016 was the busiest year, with 2. The most frequent topics are Syria, Armed Conflicts and Delivery of Health Care. Dr. Loutfi's most frequent co-authors are Haythem Y. Ali, MD, Jessica Miley Bensenhaver, MD and Lindsay F. Petersen, MD.

Dmand AI links Dr. Loutfi to 1 clinical trial. Conditions studied include Triple Negative Breast Neoplasms and Breast Neoplasms.

CMS Open Payments shows 38 general payments to Dr. Loutfi from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 40% of the total. Heron Therapeutics, Inc. paid the most, $3,484.

Dmand AI lists 1 award for Dr. Loutfi, most recently CMS Stage 1 EHR in 2013.

Dr. Loutfi graduated from Damascus University Faculty of Medicine in 1986. Dr. Loutfi is a member of ASCO.

Dr. Loutfi is in network with 14 carriers, including Aetna, Health Alliance Plan and Priority Health. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.